Kibow Biotech Inc., a scientific-diploma biotechnology agency, is celebrating its 24th Anniversary. Kibow Biotech was based on October 1, 1997, in Philadelphia and specialised in discovering, developing, and commercializing probiotic nutritional dietary dietary supplements, adhering to US FDA and FTC guidelines. The Company’s fundamental project is to provide low-priced, reachable, and orally administered dietary and health supplements at the complete for failing kidney function. Kibow platform generation is called “Enteric/Intestinal Dialysis”, which metabolizes various uremic pollution that diffuse from the circulating blood into the bowel. In addition, the exactly selected probiotic microbial lines and especially determined on prebiotics (practical fibers) product approach decrease several putrefactions generated through cardiovascular pollutants; this can clear up the dysbiotic metabolic pathways to stepped forward effects and result in higher Quality of Life (QOL) in all degrees of CKD.
The kidney fitness complement Renadyl™ for people has been advertised international thinking about the fact that 2010. This product has moreover been absolutely licensed to Centaur Pharmaceuticals, Mumbai, India, for the house, SAARC, and numerous neighboring nations, effective for the purpose that 2018. For the beyond sixteen years, the veterinary product – Azodyl™ for cats and dogs with mild to intense kidney failure end up licensed to Vetoquinol, SA (France) and set up as the #1 product for vet kidney health international.
All Kibow nutritional nutritional dietary supplements are evolved with a pharma-like validation. We are pleased to tell you that no critiques of adverse sports of any kind have been stated to the Company or US FDA with the resource of customers inside the past ten years. Despite the documented proof of safety and medical advantages to clients, get right of access to to Kibow products inside the USA is confined through way of US FDA /FTC policies, as no healthcare or illness remedy claims may be made. Been classified as dietary products, they’ll be not qualified for fitness provider prescription and any scientific repayment.
Because of these obstacles and the choice to reach and help more continual kidney patients, Kibow Pharmaceutical LLC., (www.Kibowpharma.Com) changed into released in 2019 specifically for scientific development of more moderen and superior live biotherapeutic product method through FDA/CBER approval pathway foremost to validated pharmaceutical like pharmaceuticals. Hence, the Company has opted to carry out the IND, US FDA-legal, randomized controlled Phase 2(b) scientific trial to evaluate the protection Term=nct04913272&draw=2&rank=1) has commenced out and can be carried out in approximately 20 US medical websites.
Seven medical trial internet web sites have started screening and enrolling subjects in September 2021, and the last 13 web sites are scheduled to complete recruitment amongst October and December 2021. The goal is to validate the take away of dialysis on CKD-IV patients alongside facet their man or woman popular of care with the addition of the United States-APR2020 investigative product.
Kibow Pharmaceutical has also evolved the protocol for exploratory safety and efficacy of every other stay biotherapeutic product to find out the capability to enhance dialysis adequacy, best of lifestyles and reduce dialysis period or frequency. This scientific trial is expected to kick begin in April 2022. In addition, the Company is likewise exploring a important clinical trial on pediatric CKD sufferers. We are in communique and talk with three expert Pediatric Nephrologists at their respective scientific institutions in Washington DC, North Carolina, and Texas.
Diabetes is the number one cause of kidney failure, accounting for 40 four% percentage of new times. High blood pressure is the second one main reason of kidney failure within the US after diabetes. Approximately 1 in 5 adults (20%) within the US with excessive blood stress also can have CKD. Dr. Natarajan Ranganathan, the founder, chief R&D scientist with roots from India, commented, “Kibow is looking ahead to the ones future medical (LBP) improvement milestones that might reduce the burden and immensely advantage all international persistent kidney sickness sufferers.” Besides, the goods would in all likelihood appreciably reduce Medicare and Medicaid spending through the usa fitness care machine exceeding $one hundred billion/yr on all ranges of CKD, which incorporates over six hundred,000 patients on dialysis. The “Enteric/Intestinal Dialysis” of Kibow is a novel uremic toxin removal era that aligns with AAKP desires to boost up patient alternatives, targeted remedy options, and extra get right of entry to to enhancements in the manipulate of kidney illness global.